Rhumbline Advisers Has $261,000 Stake in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Rhumbline Advisers lifted its holdings in Tyra Biosciences, Inc. (NASDAQ:TYRAFree Report) by 7.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 28,081 shares of the company’s stock after purchasing an additional 1,879 shares during the quarter. Rhumbline Advisers’ holdings in Tyra Biosciences were worth $261,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Alta Partners Management Company L.P. bought a new position in shares of Tyra Biosciences during the 4th quarter worth approximately $56,716,000. Boxer Capital Management LLC bought a new position in shares of Tyra Biosciences during the fourth quarter worth approximately $28,185,000. Farallon Capital Management LLC bought a new position in shares of Tyra Biosciences during the fourth quarter worth approximately $13,914,000. Vestal Point Capital LP bought a new position in shares of Tyra Biosciences during the fourth quarter worth approximately $13,761,000. Finally, Orbimed Advisors LLC raised its position in shares of Tyra Biosciences by 91.3% in the 4th quarter. Orbimed Advisors LLC now owns 1,470,086 shares of the company’s stock valued at $20,434,000 after buying an additional 701,448 shares in the last quarter. Institutional investors and hedge funds own 84.14% of the company’s stock.

Insider Transactions at Tyra Biosciences

In other news, Director Gilla Kaplan sold 9,568 shares of the company’s stock in a transaction on Wednesday, June 18th. The shares were sold at an average price of $9.78, for a total value of $93,575.04. Following the completion of the sale, the director now owns 28,231 shares in the company, valued at $276,099.18. This represents a 25.31% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders sold a total of 61,392 shares of company stock worth $628,358 in the last quarter. 15.20% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on TYRA. Wedbush reiterated an “outperform” rating and issued a $30.00 price target on shares of Tyra Biosciences in a research note on Friday, March 28th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Tyra Biosciences in a research report on Monday, March 31st. Finally, Piper Sandler assumed coverage on Tyra Biosciences in a research report on Wednesday, May 21st. They issued an “overweight” rating and a $33.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Tyra Biosciences presently has a consensus rating of “Buy” and an average price target of $30.83.

View Our Latest Research Report on Tyra Biosciences

Tyra Biosciences Trading Up 0.3%

TYRA opened at $9.74 on Wednesday. Tyra Biosciences, Inc. has a 1-year low of $6.42 and a 1-year high of $29.60. The company has a market cap of $517.10 million, a P/E ratio of -5.98 and a beta of 1.07. The company has a fifty day moving average price of $9.81 and a two-hundred day moving average price of $11.66.

Tyra Biosciences (NASDAQ:TYRAGet Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.02. On average, research analysts forecast that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Tyra Biosciences Company Profile

(Free Report)

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.

See Also

Want to see what other hedge funds are holding TYRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tyra Biosciences, Inc. (NASDAQ:TYRAFree Report).

Institutional Ownership by Quarter for Tyra Biosciences (NASDAQ:TYRA)

Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.